Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkp…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkp…
この記事を読む
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivi…
この記事を読む
Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. Bhagat M et al.JT…
この記事を読む
18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…
この記事を読む
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…
この記事を読む
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in R…
この記事を読む
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …
この記事を読む
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRE…
この記事を読む
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic t…
この記事を読む
Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study. Lin M e…